Edesa Biotech Inc (EDSA)
4.36
-0.04
(-0.91%)
USD |
NASDAQ |
Apr 18, 16:00
4.40
+0.04
(+0.92%)
After-Hours: 20:00
Edesa Biotech Research and Development Expense (Quarterly): 0.7045M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.7045M |
| September 30, 2023 | 0.9534M |
| June 30, 2023 | 1.026M |
| March 31, 2023 | 1.458M |
| December 31, 2022 | 1.357M |
| September 30, 2022 | 1.794M |
| June 30, 2022 | 4.548M |
| March 31, 2022 | 3.043M |
| December 31, 2021 | 3.951M |
| September 30, 2021 | 4.128M |
| June 30, 2021 | 4.464M |
| March 31, 2021 | 7.975M |
| December 31, 2020 | 1.380M |
| September 30, 2020 | 1.155M |
| June 30, 2020 | 1.144M |
| March 31, 2020 | 0.5028M |
| December 31, 2019 | 0.528M |
| September 30, 2019 | 0.4818M |
| June 30, 2019 | 0.5029M |
| March 31, 2019 | 0.3757M |
| December 31, 2018 | 0.4703M |
| September 30, 2018 | 0.4973M |
| June 30, 2018 | 0.4652M |
| March 31, 2018 | 0.4939M |
| December 31, 2017 | 0.631M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.647M |
| June 30, 2017 | 0.5362M |
| March 31, 2017 | 0.3294M |
| December 31, 2016 | 0.4609M |
| September 30, 2016 | 0.6614M |
| June 30, 2016 | 0.4701M |
| March 31, 2016 | 0.3091M |
| December 31, 2015 | 0.2888M |
| September 30, 2015 | 0.1994M |
| June 30, 2015 | 0.1297M |
| March 31, 2015 | 0.2816M |
| December 31, 2014 | 0.4188M |
| August 31, 2014 | 1.088M |
| May 31, 2014 | 0.4621M |
| February 28, 2014 | 0.5366M |
| November 30, 2013 | 0.3718M |
| August 31, 2013 | 1.334M |
| May 31, 2013 | 0.1782M |
| February 28, 2013 | 0.2368M |
| November 30, 2012 | 0.2696M |
| August 31, 2012 | 1.414M |
| May 31, 2012 | 0.3322M |
| February 29, 2012 | 0.3753M |
| November 30, 2011 | 0.5125M |
| August 31, 2011 | -0.1734M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.4818M
Minimum
Sep 2019
7.975M
Maximum
Mar 2021
2.163M
Average
1.357M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Acasti Pharma Inc | 1.443M |
| Aurinia Pharmaceuticals Inc | 10.23M |
| Lexaria Bioscience Corp | 0.2458M |
| Xenon Pharmaceuticals Inc | 41.08M |
| ESSA Pharma Inc | 5.377M |